Traders should expect extreme volatility and potential suspension of trading. The May 26 stay request deadline is the next catalyst — if denied, shares could be halted immediately. Avoid holding through the Panel decision unless a clear cure plan emerges.
Price Chart
Executive Summary
XTL Biopharmaceuticals received a Staff delist determination from Nasdaq on May 18, 2026, due to failure to file its Annual Report on Form 20-F for FY2025, adding a third deficiency to its existing non-compliance with minimum stockholders' equity ($2.5M) and minimum bid price ($1) rules. The company must request a stay of suspension by May 26, 2026, and faces imminent delisting risk with no assurance the Panel will grant continued listing.
Key Facts
- Nasdaq Staff notified XTL on May 18, 2026, of delisting determination for failure to file FY2025 Annual Report on Form 20-F (Rule 5250(c)(1)).
- Company already faces delisting proceedings for non-compliance with minimum $2.5M stockholders' equity (Rule 5550(b)(1)) and minimum $1 bid price (Rule 5550(a)(2)).
- Deadline to request a stay of suspension is May 26, 2026; Panel decision expected within 15 calendar days thereafter.
- Market cap is approximately $6M, making this a micro-cap with limited resources to appeal or cure deficiencies.
Financial Impact
Imminent delisting risk for a $6M market cap company; no financial figures provided in filing.
Risk Factors
- Nasdaq Panel may deny the stay request, leading to immediate suspension and delisting.
- Company has three simultaneous listing deficiencies with no disclosed plan to cure any of them.
- Micro-cap with $6M market cap has limited financial flexibility to regain compliance or appeal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060565 |
| Document: ea029190401ex99-1.htm | 0001213900-26-060565 |
| Document: 0001213900-26-060565-index-headers.html | 0001213900-26-060565 |
| Document: 0001213900-26-060565-index.html | 0001213900-26-060565 |
| Document: 0001213900-26-060565.txt | 0001213900-26-060565 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $1.91 | awaiting T+60 | — | $1.78 (−6.81%) |
Jun 30, 2026 16w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.78 (+28.51%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.78 (−34.80%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.78 (+25.21%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.78 (−33.33%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.78 (−50.00%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.78 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers